Tuberous sclerosis complex 2 protein (TSC2)

Tuberous sclerosis complex 2 protein, commonly referred to as Tuberin, is a vital tumor suppressor that functions as a key negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway [UniProt: P49815]. In association with TSC1, it acts as a GTPase-activating protein (GAP) for the small GTPase Rheb, converting it into its inactive GDP-bound state and thereby suppressing cell growth and protein synthesis [PubMed: 12172553]. Loss-of-function mutations in the TSC2 gene are the primary cause of Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM), characterized by the formation of benign tumors (hamartomas) in various organs including the brain, heart, and kidneys [StatPearls: NBK441887]. Because TSC2 deficiency leads to constitutive hyperactivation of mTORC1, therapeutic strategies have historically focused on mTOR inhibitors such as Sirolimus and Everolimus to mitigate disease progression and reduce tumor volume [PubMed: 21829363]. Recent advancements are exploring gene therapy approaches to restore TSC2 function directly, aiming for a more definitive treatment for affected patients [PubMed: 33434131]. This protein serves as a central hub integrating signals from the PI3K/Akt and AMPK pathways to maintain cellular homeostasis in response to nutrient availability and growth factors.

Other names

TuberinTSC2Lymphangioleiomyomatosis proteinPPP1R160

TSC2 functions as a GTPase-activating protein (GAP) for the small GTPase Rheb; by stimulating the intrinsic GTPase activity of Rheb, it converts Rheb-GTP to Rheb-GDP, thereby inactivating Rheb and inhibiting the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway [UniProt: P49815, PubMed: 12172553].